- Associated Press•14 hours ago
The Bothell, Washington-based company said it had a loss of 23 cents per share. The results beat Wall Street expectations. The average estimate of 10 analysts surveyed by Zacks Investment Research was ...
- Business Wire•15 hours ago
Seattle Genetics, Inc. today reported financial results for the third quarter and nine months ended September 30, 2016. The company also highlighted ADCETRIS commercialization and clinical development accomplishments, vadastuximab talirine activities and progress with its pipeline of antibody-drug conjugates and other proprietary programs.
Seattle Genetics, Inc. (SGEN)
NasdaqGS - NasdaqGS Real Time Price. Currency in USD
|Bid||45.00 x 100|
|Day's Range||49.77 - 51.63|
|52wk Range||26.02 - 57.83|
|1y Target Est||N/A|
Trade prices are not sourced from all markets
|P/E Ratio (ttm)||-65.35|
|Avg Vol (3m)||810,696|
|Dividend & Yield||N/A (N/A)|